MolPharm

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


Molecular Pharmacology Fast Forward
First published on July 11, 2008; DOI: 10.1124/mol.108.048207


0026-895X/08/7404-980-989$20.00
Mol Pharmacol 74:980-989, 2008

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
mol.108.048207v1
74/4/980    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Guerreiro, S.
Right arrow Articles by Michel, P. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Guerreiro, S.
Right arrow Articles by Michel, P. P.

Paraxanthine, the Primary Metabolite of Caffeine, Provides Protection against Dopaminergic Cell Death via Stimulation of Ryanodine Receptor Channels

Serge Guerreiro, Damien Toulorge, Etienne Hirsch, Marc Marien, Pierre Sokoloff, and Patrick P. Michel

Institut National de la Santé et de la Recherche Médicale, Unité Mixte de Recherche S679, Experimental Neurology and Therapeutics, Paris, France (S.G., D.T., E.H., P.P.M.); Université Pierre et Marie Curie-Paris 6, Paris, France (S.G., D.T., E.H., P.P.M.); and Centre de Recherche Pierre Fabre, Castres, France (M.M., P.S., P.P.M.)

Epidemiological evidence suggests that caffeine or its metabolites reduce the risk of developing Parkinson's disease, possibly by protecting dopaminergic neurons, but the underlying mechanism is not clearly understood. Here, we show that the primary metabolite of caffeine, paraxanthine (PX; 1, 7-dimethylxanthine), was strongly protective against neurodegeneration and loss of synaptic function in a culture system of selective dopaminergic cell death. In contrast, caffeine itself afforded only marginal protection. The survival effect of PX was highly specific to dopaminergic neurons and independent of glial cell line-derived neurotrophic factor (GDNF). Nevertheless, PX had the potential to rescue dopaminergic neurons that had matured initially with and were then deprived of GDNF. The protective effect of PX was not mediated by blockade of adenosine receptors or by elevation of intracellular cAMP levels, two pharmacological effects typical of methylxanthine derivatives. Instead, it was attributable to a moderate increase in free cytosolic calcium via the activation of reticulum endoplasmic ryanodine receptor (RyR) channels. Consistent with these observations, PX and also ryanodine, the preferential agonist of RyRs, were protective in an unrelated paradigm of mitochondrial toxin-induced dopaminergic cell death. In conclusion, our data suggest that PX has a neuroprotective potential for diseased dopaminergic neurons.


Received April 24, 2008; accepted July 11, 2008

Address correspondence to: Dr. Patrick P. Michel, Unité Mixte de Recherche Institut National de la Santé et de la Recherche Médicale/Université Pierre et Marie Curie-Paris-6, Bât. Pharmacie, Hôpital de la Salpêtrière, 47, bd de l'hôpital, 75013 Paris, France. E-mail: patrick-pierre.michel{at}upmc.fr







Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2008 by the American Society for Pharmacology and Experimental Therapeutics